Dr Rosenthal’s experience in the biotechnology industry spans more than 20 years and encompasses the management of global clinical programs, regulatory affairs, quality assurance (GxP), and intellectual property at companies in the oncology field. She was a key member of the Viralytics team acquired by Merck in June 2018 - the largest ever transaction in the Australian biotech sector.

While serving as Director Quality and Regulatory Affairs at Viralytics, Dr Rosenthal set the global regulatory strategy for the company’s oncolytic viral therapy, liaising with international regulatory agencies such as the US FDA and the EMA. Previously she served as Director of Clinical and Regulatory Affairs at Alchemia, where she managed the clinical development of its late-stage oncology product pipeline, including a global pivotal Phase III clinical trial. Prior to that, she held positions at Florigene and at Davies, Collins, and Cave Patent and Trade Mark Attorneys. She holds a PhD in genetics and molecular biology from Monash University in Australia and did post-doctoral research at Vanderbilt University in the USA.